Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation.
João Paulo ColaThiago Nascimento do PradoBárbara Almeida CamposBárbara Juliana Pinheiro BorgesBárbara Manuella Cardoso Sodré AlvesSonia Vivian de JezusCarolina Maia Martins SalesWildo Navegantes de AraújoNoemia Urruth Leão TavaresEthel Leonor Noia MacielPublished in: PloS one (2023)
It is expected that with the treatment with the 300 mg formulation, more patients will complete the treatment based on the complexity index of pharmacotherapy. Our study intends to substantiate theoretical and operational strategies that respond to the demand for incorporation of a new formulation of the drug for the treatment of LTBI in the Unified Health System network.